Anavex Life Sciences Corp (AVXL)

[bb8675309]

AVXL- Best in class in the CNS biotech space.

"We are excited with the continued advancement of our lead product candidate ANAVEX 2-73 in Alzheimer disease and Rett syndrome as we maintain our attention on execution across each of our clinical programs, and overall business operations. We were very pleased to present top line data of the randomized double-blind placebo controlled Phase 2b/3 study for the treatment of early Alzheimer disease at the CTAD Congress 2022 on December 1. The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints".